What is it?
A collaborative effort to operate as an adjunct to AOPA’s ongoing ‘Survival Imperatives.’ Prosthetics 2020 is a partnership open to interested companies who want to take a strong, proactive role in shaping the drivers of prosthetic patient care five years down the road. If you share a commitment to protect, fortify, and enhance the recognized, scientifically-substantiated value of prosthetic care in the minds of payers, patients and the general public, you will want to consider making an investment to be part of Prosthetics 2020.
What is the Purpose and the Goals?
To protect and grow the Lower Extremity Prosthetic (“LEP”) market through an outcomes based medicine approach that timely prosthetic services saves lives and money. This will be accomplished by:
1. Defining and establishing the health economic value of current LEP products/services (K3/K4)
2. Expanding the value of LEP products/services by defining new patient indications and population that will benefit from current and new prosthetic technologies (K1/K2)
The goals are to:
1. Improve the future reimbursement landscape for LEP
2. Define and provide the appropriate technology to the appropriate patients to reduce the current trend of providing the lowest cost technology to all patients
3. Define new patient segments that can benefit from LEP technology
4. Separate the O&P profession from Durable Medical Equipment (DME) in the mind of the payers.
Who is Involved?
To ensure clinical efficacy a Medical Advisory Board (MAB) was created to provide the necessary clinical knowledge to oversee research development and communicate the findings to patients, providers and payers, including CMS.
Medical Advisory Board
|Michael Jaff, DO
Mass General Vascular Center
|Kenton R. Kaufman, PhD
W. Hall Wendel Jr. Musculoskeletal Research Professor
|Paul F. Pasquina, MD
Walter Reed Army Medical Center
|Douglas G. Smith, MD
Harborview Medical Center, University of Washington Medical Center
AOPA will be managing this effort with the assistance of a small expert Steering Committee to be appointed by AOPA’s President. The Steering Committee is responsible for advancing research proposals, coordinating with the Medical Advisory Board and making other recommendations/decisions, subject to the overall AOPA governance framework via the AOPA Board of Directors.
- James Campbell, PhD, CO, FAAOP, Hanger Clinic, Chief Clinical Officer, Austin, TX
- Maynard Carkhuff, Vice Chairman and Chief Innovation Officer at Freedom Innovations
- Jim Colvin, Director of Engineering, WillowWood, Mount Sterling, OH
- Charles H. Dankmeyer, Jr., CPO, Arnold, MD
- Kim DeRoy, MSc, RPT, VP of Prosthetics Sales and Marketing, Össur, Foothill Ranch, CA
- Andreas Kannenberg, MD, PhD, Executive Medical Director, North America, Ottobock, Austin, TX
- Michael Oros, CPO, LPO, FAAOP, President & CEO, Scheck & Siress, Oak Park, IL
- Sam Liang, MBA, President, COO, Hanger Clinic, Austin, TX
- David Moser, PhD, BEng, BSc, Head of Research, Endolite Technology Centre, Hampshire, UK
- Thomas F. Fise, JD is executive director of AOPA
- Freedom Innovations
- Scheck & Siress
The RAND Research Project
The first project undertaken in the Prosthetics 2020 initiative is the RAND Research Project. After reviewing proposals from RAND Corporation and two other health economics “think tanks,” AOPA commissioned RAND Corporation to complete a comprehensive, independent, validated study to establish the value proposition for prosthetic services to amputees, which focuses on advanced prostheses and includes K2/K3 comparisons. RAND will be expanding its initial scope to include economic analysis for three types of transtibial prostheses, including dynamic response (energy storing and release) foot, microprocessor controlled ankle foot system, and powered ankle foot system. The results will be incorporated into the final report that covers both advanced transfemoral and transtibial prostheses. In addition to the study and final report, it is expected that this joint effort will likely end up comprised of three components- the study and final report, as well as a free-standing modeling tool based on the RAND simulation and a white paper outlining AOPA’s vision. We anticipate this project to be completed in early 2017.